Do you plan to offer adjuvant olaparib to all gBRCA+ breast cancer whether TNBC or HR+?

In subset analyses of OlympiA there seems to be smaller magnitude of benefit among HR+ patients. In your opinion, should adjuvant olabarib be offered to all patients regardless of HR status or reserved for higher risk TNBC population?

Answer from: Medical Oncologist at Academic Institution

I offer adjuvant olaparib to germline BRCA mutated breast cancer patients (TNBC or hormone receptor positive and Her-2 negative) only if they meet the inclusion criteria that was used in the OlympiA study, which is as follows:1) Patients with triple-negative breast cancer who were treated with adjuv...

Comments

Medical Oncologist at Colorado Permanente Medical Group Hematology & Oncology
If a patient with TNBC T1cNo and gBRCA1+ went to s...

Answer from: Medical Oncologist at Academic Institution

I plan to offer adjuvant olaparib to all high risk gBRCA+ breast cancer given the benefit demonstrated in the ITT population of the OlympiA trial. These cancers are driven by the gBRCA mutation and there is no evidence that olaparib was less effective in HR+ patients. The subgroup analysis at median...

Answer from: Medical Oncologist at Academic Institution

Currently, the data support treating all germline BRCA positive patients that are high risk (TNBC or HR+) with Olaparib in the adjuvant setting.

Please select the option that best describes you:

Do you plan to offer adjuvant olaparib to all gBRCA+ breast cancer whether TNBC or HR+?

Related Questions